Frank Milton Balis, M.D.

faculty photo
Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
The Louis and Amelia Canuso Family Endowed Chair for Clinical Research in Oncology, The Children's Hospital of Philadelphia Philadelphia, PA
Co-Leader, Clinical Pharmacology Research Affinity Group, Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
3501 Civic Center Blvd., Room CTRB4024
Philadelphia, PA 19104
Office: 267-426-5414
Fax: 267-425-5839
B.S. (Zoology)
University of North Carolina, 1971.
M.D. (Medicine)
Vanderbilt University, 1975.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Solid tumors in children, renal tumors in children, clinical pharmacology of anticancer drugs

Description of Other Expertise

Clinical research infrastructure and informatics

Description of Research Expertise

Clinical pharmacology of anticancer drugs, cancer biomarkers, clinical trial design

Selected Publications

258. Mittal S, Long C, El-Ali A, Talwar R, Lattanzio K, Lawton B, Hamdan D, Balis FM, Mattei P, Back SJ, Kolon TF: Utilizing RENAL nephrometry in pediatric patients undergoing nephron-sparing surgery for renal tumors. J Pediatr Urol Page: Pub, 2023.

257. Singh P, Crossman DK, Zhou L, Wang X, Sharafeldin N, Hageman L, Blanco JG, Burridge PW, Armenian SH, Balis FM, Hawkins DS, Keller FG, Hudson MM, Neglia JP, Ritchey AK, Ginsberg JP, Landier W, Bhatia S: Haptoglobin gene expression and anthracycline-related cardiomyopathy in childhood cancer survivors: A COG-ALTE03N1 report. JACC CardioOncol 5: 392-401, 2023.

256. Lai C, Cole DE, Steinberg SM, Lucas N, Dombi E, Melani C, Roschewski M, Balis FM, Widemann BC, Wilson WH: Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment. Blood Adv 7: 529-32, 2023.

Busch CM and Balis FM: Age-dependent reference intervals in children for the disialoganglioside, G(D2), a circulating tumor biomarker for the childhood cancer, neuroblastoma. Clin Biochem 101: 1-4, 2022.

Moon JK, Hwang R, Balis FM, Mattei P: An enhanced recovery after surgery protocol in children who undergo nephrectomy for Wilms tumor safely shortens hospital stay. J Pediatr Surg In Press, 2022.

Fox E, Busch C, DeBernardo A, Segers B, Gottschalk J, Womer R, Balamuth N, Bagatell R, Balis F.: A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma. Cancer Chemother Pharmacol 87: 807-815, Jun 2021.

Foster JH, Voss SD, Hall DC, Minard CG, Balis FM, Wilner K, Berg SL, Fox E, Adamson PC, Blaney SM, Weigel BJ, Mossé YP.: Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res lin Cancer Res, 2021.

Balis F, Green DM, Anderson C, Cook S, Dhillon J, Gow K, Hiniker S, Jasty-Rao R, Lin C, Lovvorn H, MacEwan I, Martinez-Agosto J, Mullen E, Murphy ES, Ranalli M, Rhee D, Rokitka D, Tracy EL, Vern-Gross T, Walsh MF, Walz A, Wickiser J, Zapala M, Berardi RA, Hughes M: Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19: 945-977, 2021.

Balis FM, McCully CL, Busch CM, Fox E, Warren KE.: Pharmacokinetics of the disialoganglioside, G D2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates. J Circ Biomark 10: 26-29, 2021.

Greengard E, Mosse YP, Liu X, Minard CG, Reid JM, Voss S, Wilner K, Fox E, Balis F, Blaney SM, Adamson PC, Weigel BJ.: Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemother Pharmacol 86: 829-840, Dec 2020.

back to top
Last updated: 07/17/2023
The Trustees of the University of Pennsylvania